About Peroxisomal targeting signal 2 receptor
Peroxisomal targeting signal 2 receptor (PEX7) is a protein
from Homo sapiens identified by UniProt accession
O00628, 323 residues long.
MolForge cross-references it against 0 known binders and
76 disease associations.
Target properties
| Protein name | Peroxisomal targeting signal 2 receptor |
|---|
| UniProt accession | O00628 |
|---|
| Gene | PEX7 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 323 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (76)
Diseases linked to this target (Open Targets).
- rhizomelic chondrodysplasia punctata type 1 · score 0.82
- Refsum disease · score 0.79
- rhizomelic chondrodysplasia punctata · score 0.53
- Joubert syndrome and related disorders · score 0.49
- neurodegenerative disease · score 0.48
- genetic disorder · score 0.47
- connective tissue disease · score 0.39
- peroxisome biogenesis disorder · score 0.37
- neutrophil count · score 0.28
- Abnormality of metabolism/homeostasis · score 0.27
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O00628-F1 | alphafold | PREDICTED | 94.99 | — |
Amino-acid sequence (323 residues)
MSAVCGGAAR MLRTPGRHGY AAEFSPYLPG RLACATAQHY GIAGCGTLLI LDPDEAGLRL FRSFDWNDGL FDVTWSENNE HVLITCSGDG SLQLWDTAKA AGPLQVYKEH AQEVYSVDWS QTRGEQLVVS GSWDQTVKLW DPTVGKSLCT FRGHESIIYS TIWSPHIPGC FASASGDQTL RIWDVKAAGV RIVIPAHQAE ILSCDWCKYN ENLLVTGAVD CSLRGWDLRN VRQPVFELLG HTYAIRRVKF SPFHASVLAS CSYDFTVRFW NFSKPDSLLE TVEHHTEFTC GLDFSLQSPT QVADCSWDET IKIYDPACLT IPA
Explore Peroxisomal targeting signal 2 receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets